Phase I Study of Weekly Bortezomib (VELCADE, PS-341) and Weekly Topotecan (HYCAMTIN) in Solid Tumor Patients With an Emphasis on Small Cell Lung Cancer (SCLC).
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2010
At a glance
- Drugs Bortezomib; Topotecan
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 28 Jun 2010 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
- 22 Jan 2008 Status changed from recruiting to completed according to NCT.